Technical Snapshots for These Biotech Stocks -- BioPharmX, bluebird bio, Calithera Biosciences, and Capricor Therapeutics

Monday, May 7, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 7, 2018 /PRNewswire/ --

If you want a free Stock Review on BPMX, BLUE, CALA, and CAPR sign up now at Pre-market, draws investors' attention to BioPharmX Corp. (NYSE AMER: BPMX), bluebird bio Inc. (NASDAQ: BLUE), Calithera Biosciences Inc. (NASDAQ: CALA), and Capricor Therapeutics Inc. (NASDAQ:
CAPR). Biotechnology companies are those that employ living organisms or biological substances for the development of products and services with applications in numerous fields, such as waste management, food processing, agriculture, and pharmaceutics. All you have to do is sign up today for this free limited time offer by clicking the link below.


Menlo Park, California headquartered BioPharmX Corp.'s stock finished last Friday's session 4.33% lower at $0.20. A total volume of 8.86 million shares was traded. The Company's shares have advanced 23.53% over the previous three months. The stock is trading below its 200-day moving average by 12.09%. Additionally, shares of BioPharmX, which develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets, have a Relative Strength Index (RSI) of 33.90.  

On April 26th, 2018, BioPharmX reports its results for the quarter and year ended January 31st, 2018. For Q4 FY18, total operating expenses were $3.6 million, and net loss was $3.8 million. For FY18, total operating expenses were $16.7 million, and net loss was $16.6 million. As of January 31st, 2018, cash and cash equivalents were $7.6 million. Get the full research report on BPMX for free by clicking below at:

bluebird bio

On Friday, shares in Cambridge, Massachusetts headquartered bluebird bio Inc. ended the session 2.65% higher at $174.10. The stock recorded a trading volume of 471,387 shares. The Company's shares have gained 2.32% in the last month and 86.80% over the past year. The stock is trading 10.00% above its 200-day moving average. Moreover, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and cancer, have an RSI of 46.62.  

On May 02nd, 2018, bluebird bio reported its results for the quarter ended March 31st, 2018. Total revenues for Q1 2018 were $16.0 million; R&D expenses were $97.1 million; G&A expenses were $34.9 million; and net loss was $115.1 million. As of March 31st, 2018, cash, cash equivalents, and marketable securities were $1.57 billion. Access the free research report on BLUE now by signing up at:

Calithera Biosciences

South San Francisco, California headquartered Calithera Biosciences Inc.'s shares gained slightly by 0.78%, closing the session at $6.50 with a total trading volume of 346,904 shares. The stock has gained 11.11% in the last month. The stock is trading 4.86% below their 50-day moving average. Additionally, shares of Calithera Biosciences, which focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have an RSI of 48.60.  

On April 25th, 2018, Calithera Biosciences announced that three abstracts describing CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO). ASCO will be held from June 01st, 2018, to June 07th, 2018, in Chicago, Illinois. Are you already registered with Wall St. Equities? Do so now for free, and get the report on CALA at:

Capricor Therapeutics

Last Friday at the close, shares in Beverly Hills, California headquartered Capricor Therapeutics Inc. recorded a trading volume of 85,794 shares. The stock ended the session 3.13% higher at $1.32. The Company's shares are trading below their 50-day moving average by 14.23%. Furthermore, shares of Capricor Therapeutics, which focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions, have an RSI of 41.15.  

On May 04th, 2018, Capricor Therapeutics announced that it will report its Q1 2018 financial results and corporate update shortly after the NASDAQ market close on May 10th, 2018. Management will host a webcast and conference call at 4:30 p.m. ET that same day. Aspiring Member, please take a moment to register below for your free research report on CAPR at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store